The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination.
The globalization of the world's economies, accompanied by increasing international travel, changing climates, altered human behaviour and demographics is leading to the emergence of different viral diseases, many of which are highly pathogenic and hence are considered of great public and animal health importance. To undertake basic research and therapeutic development, many of these viruses require handling by highly trained staff in BSL-3/4 facilities not readily available to the majority of the global R&D community. In order to circumvent the enhanced biosafety requirement, the development of non-pathogenic, replication-defective pseudotyped viruses is an effective and established solution to permit the study of many aspects of virus biology in a low containment biosafety level (BSL)-1/2 laboratory. Under the spectre of the unfolding Ebola crisis, this timely conference (the second to be organised by the Viral Pseudotype Unit, www.viralpseudotypeunit.info*) discusses the recent advances in pseudotype technology and how it is revolutionizing the study of important human and animal pathogens (human and avian influenza viruses, rabies/lyssaviruses, HIV, Marburg and Ebola viruses). Key topics addressed in this conference include the exploitation of pseudotypes for serology and serosurveillance, immunogenicity testing of current and next-generation vaccines and new pseudotype assay formats (multiplexing, kit development). The first pseudotype-focused Euroscicon conference organised by the Viral Pseudotype Unit was recently reviewed [1].
VPU Fitzrovia, Faculty of Science and Technology, University of Westminster, 115 New Cavendish Street, London W1W 6UW, United Kingdom.
Emma M
EM
Bentley
VPU Medway, Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham Maritime, Kent ME4 4TB, United Kingdom.
Stuart T
ST
Mather
VPU Medway, Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham Maritime, Kent ME4 4TB, United Kingdom. Electronic address: n.temperton@kent.ac.uk.
Nigel J
NJ
Temperton
D000818:Animals; D029043:Ebolavirus; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control; D006801:Humans; D011819:Rabies Vaccines; D014611:Vaccination; D014612:Vaccines; D014780:Viruses / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity*
D011819:Rabies Vaccines; D014612:Vaccines
Pseudotyped virus; Serology; Vaccine; Zoonotic virus